Electrical stimulation studies have implicated the medial medulla in the inhibition of muscle tone. In the present report we present evidence for suppression of muscle tone by chemical activation of the medial medulla. We find 2 distinct zones within the classically defined medial medullary inhibitory area. A rostra1 region corresponding to the nucleus magnocellularis (NMC) is sensitive to glutamate. Atonia produced by activation of this region is mediated by non-NMDA receptors.
A caudal region, corresponding to the nucleus paramedianus (NPM) is sensitive to ACh. Atonia produced by activation of this region is mediated by muscarinic receptors. Activation of these regions both in acute decerebrate and intact cats suppresses muscle tone. We find that the cholinoceptive dorsolateral pontine region, previously implicated in atonia control, can be activated by glutamatesensitive non-NMDA receptors. Microinjection of atropine into the NPM or of glutamylglycine into the NMC blocks atonia elicited by pontine carbachol injection.
The medullary regions identified here are hypothesized to mediate the suppression of muscle tone that occurs in rapid eye movement sleep and in cataplexy and may have a role in postural control in waking. Magoun (1944) and Magoun and Rhines (1946) first reported that electrical stimulation of the medial medulla produced a complete suppression of muscle tone. Neurons or pathways in this region are thought to mediate the muscle tone suppression that occurs during rapid eye movement (REM) sleep and during cataplectic episodes in narcoleptics (Morrison, 1983; Siegel et al., 1989) . However, because electrical stimulation activates both fibers of passage and cell bodies, the location of the neuronal somas responsible for medullary inhibition and the transmitters to which they might respond have been unclear. A number of studies have shown that choline& stimulation of the dorsolateral pons elicits atonia (George et al., 1964; Baxter, 1969; Mitler and Dement, 1974; Baghdoyan et al., 1984; Katayama et al., 1984; Shiromani et al., 1986) . However, repeated investigations have shown that cholinergic stimulation of the presumed rostra1 medullary inhibitory region does not produce atonia (Baghdoyan et al., 1984; Shiromani et al., 1986) .
In the present study, we demonstrate that atonia can be generated by chemical stimulation of 2 distinct regions of the medial medulla, the nucleus magnocellularis (NMC) of the rostra1 medulla and the nucleus paramedianus (NPM) of the caudal medulla. Glutamatergic, but not cholinergic, stimulation of the NMC produces atonia. Cholinergic, but not glutamatergic, stimulation of the NPM produces atonia. These data reveal a previously unknown chemical and anatomical organization in the pontomedullary "inhibitory system." A brief report of these findings has appeared ).
Materials and Methods
Acute studies were performed on 30 unanesthetized cats decerebrated at the precollicular level under halothane anesthesia, as previously described (Iai et al., 1987) . Chronic studies were performed on unanesthetized unrestrained cats. Details of the chronic cannula implant and injection procedures have been presented (Shiromani et al., 1986) . The inhibitory areas in pontine and medial medullary reticular formation (PRF and MMRF) were identified by electrical stimulation (500 msec trains at 100 Hz, 20-60 /IA, 0.2 msec cathodal rectangular pulses). When a point at which electrical stimulation produced bilateral suppression of muscle tone (with onset within 10 msec in the splenius, occipitoscapularis, and biventer cervicis muscles) was identified, the stimulating electrode was removed and 0.5 ~1 of the agonist test solution was injected. Microinjections were made through a 26-gauge Hamilton 1 ~1 microsyringe over a period of 1 min. In studies in which the action of antagonist (or control Ringer's) was examined, antagonist injections were performed 1 hr after baseline agonist injections. Five minutes later the agonist was reapplied. Agonist was microinjected after 1 hr to confirm ihe return of-baseline response. Unilateral injections were performed in all mannina studies, while bilateral NMC and NPM iniections were utilized to*block atonia elicited by pontine carbachol injection. Target areas ranged from P3-P5, LO-L3 in PRF and P8-P15, LO-L2 in MMRF. At the end ofthe infusion studies, current was passed through a microelectrode to deposit iron at the most ventral point of injection.
The animals were perfused with saline followed by 10% formalin solution. The brain stems were removed, stored in 30% sucrose-formalin solution, and then cut serially at 40 pm. Staining with Neutral red and counterstaining with ferrocyanide was used to localize the injection sites.
All chemicals were dissolved in Ringer's solution and adjusted to a pH of 7.4, at the concentrations of 0.05-0.4 M of L-glutamic acid (glutamate), 0.2 M of L-glutamic acid diethyl ester @DEE), 10 mM of gamma-o-glutamyglycine (DGG), 50 mM of m-2-amino-5-phosphonovaleric acid (APV), 1.4-6.8 mM ofN-methyl-D-aspartic acid (NMDA), 9.0 ~~-0.9 mM of kainic acid (KA), 0.2-5.0 mM of quisqualic acid (QA), 1.1 M of ACh, 44-l 00 mM of carbachol, and 7 mM of atropine.
Results
Microinjection of glutamate into the PRF and ventral rostromedial medullary reticular formation (rMMRF) produced bilateral inhibition of muscle tone (Fig. 1, Table 1 ). Ringer's vehicle injection did not produce any effect on muscle tone. Microinjection of glutamate into caudal MMRF (cMMRF) did not produce atonia (20/21 sites in 8 cats; p < 0.001, x2). The effective points in rMMRF were concentrated in the NMC (Fig.  2) . Injections of glutamate at points in the dorsal rMMRF did not induce any change of muscle activity or increased muscle tone, even though electrical stimulation of these points produced atonia. Similarly, glutamate injection in trapezoid body, pyramidal tract, and other areas in which electrical stimulation increased muscle tone had no effect or increased activity. The magnitude and duration of the inhibition produced by glutamate injection in the NMC was dose dependent (Fig. 3) . At 0.05 M, glutamate injection produced only a small decrease in tone, with none of the 6 muscles recorded completely atonic. At 0.1 M, all 6 recorded muscles showed decreased tone, although none was completely atonic. At a 0.2 M dose, 4 muscles were completely atonic, while at 0.4 M, all six muscles were completely atonic. The duration of inhibition below baseline values was also dose dependent (Fig. 3) .
To identify receptors involved in the mediation of muscle inhibition, receptor antagonists were microinjected intracerebrally. DGG, which is a NMDA and KA receptor antagonist, blocked glutamate-induced muscle inhibition in the pons (8/8 sites in 7 cats) and in the NMC (1 l/l 1 sites in 8 cats; Fig. 1 ). GDEE, which is a NMDA and QA receptor antagonist (Davies and Watkins, 1981) , blocked or attenuated the effect of glutamate on muscle activity in both PRF (8/8 sites in 8 cats) and NMC (6/7 sites in 7 cats). However, APV, which is a highly specific NMDA receptor blocker (Jones et al., 1984) did not block the glutamate-induced atonia in the pons (8/9 sites in 5 cats) or in the NMC (414 sites in 3 cats). The differences in antagonist effects were highly significant in both PRF and rMMRF (p < 0.001, x2), indicating that glutamate-induced suppression of muscle tone in the PRF and NMC is mediated by non-NMDA receptors.
Agonist studies confirmed this conclusion. NMDA injected into either PRF (3 sites in 2 cats) or NMC (6 sites in 2 cats) produced excitatory or mixed effects on muscle activity. At doses below 2.7 mM, NMDA produced only excitation. At 6.8 mrq NMDA produced excitation followed by inhibition. In contrast, low doses of KA (9-90 PM) did not produce any change in muscle activity, while higher doses (0.15-0.2 mM) induced bilateral inhibition. This inhibition was not due to depolarization blockade, since doses up to 0.9 mM still produced inhibition, and repeated injections at the same site produced repeated Table 1 . Latency and duration (*SD) of atonia elicited by microinjection (doses listed in Fig. 2 Figure   3 . Effect of glutamate concentration on the magnitude and duration of motor inhibition. Magnitude was calculated with reference to integrated EMG amplitude in 3 min baseline period. Concentration of glutamate was varied from 0.05 to 0.4 M in counterbalanced order. Curves are fit with cubic spline interpolations. Each point is based on the mean activity in the 6 recorded muscles (left and right occipitoscapularis, splenius, and biventer cervicis).
inhibition, indicating that the neuronal elements mediating the atonia response were not damaged by effective injections. Similar results were found after QA injection. The threshold for QA-evoked inhibition was 0.2 mM, comparable to that seen for KA. Both ACh and its agonist, carbachol, were found to induce muscle atonia in PRF and cMMRF (Table 1) but not in rMMRF (p < 0.001, x2). Microinjected atropine blocked the effect of ACh on muscle activity at both sites (Fig. 4) . Effective sites in the medulla corresponded to the NPM (Fig. 2) . Carbachol microinjection into NPM (3/3 in 3 cats) produced a longer latency (mean, 2.4 f 0.8 min) suppression of muscle activity. Complete loss of muscle tone after carbachol lasted for more than 4 hr and was followed by alternation of episodes of atonia and muscle activity for another 12 hr. In rMMRF, injection of ACh had no effect on muscle activity (15/l 7 in 10 cats; p < 0.00 1, x2),. However, carbachol injection induced muscle atonia after a very long latency (> 20 min). ACh is rapidly inactivated by hydrolysis, while carbachol is completely resistant to hydrolysis by both acetylcholinesterase and plasma pseudocholinesterase (Wurzel, 1959) . Therefore, the presence of atonia at long latencies after infusion of carbachol into rMMRF is likely to be due to carbachol diffusion into PRF and/or NPM rather than a direct effect on the neurons in the rMMRF.
We found that bilateral microinjection of DGG into NMC blocked pontine carbachol-induced atonia (3/3 in 3 cats; indicates that both NPM and NMC contribute to the mediation of pontine elicited carbachol atonia. We injected ACh (1.1 M) and glutamate (0.1 M) in 2 unanesthetized cats, aiming at the areas defined in our acute studies. We used chronically implanted 23-gauge guide cannulas to position 29-gauge injection cannulas, following the injection procedures described above. We found that glutamate injections in NMC and ACh injections in NPM reduced muscle tone in both chronic animals, as in the decerebrate (Fig. 6 ).
Discussion
The medullary inhibitory area defined by the present study is considerably smaller than the medullary inhibitory area indicated by electrical stimulation studies. Furthermore, it can be subdivided into 2 pharmacologically distinct zones: a glutamatesensitive zone in the rMMRF corresponding to the NMC and an ACh-sensitive zone in the cMMRF corresponding to the NPM. The rostra1 medullary region was sensitive to glutamate, but insensitive to ACh, while the caudal medullary region was sensitive to ACh, but insensitive to glutamate. The pontine atonia generating area, which corresponds to the dorsal portion of the nucleus pontis centralis oralis (Taber, 196 l) , and the pet-i-locus coeruleus or (Sakai, 1980) , was sensitive to both glutamate and ACh. Pontine and medullary glutamate-sensitive sites were found to utilize non-NMDA receptors.
Although electrical stimulation of the medulla generates atonia, the medullary region is not sufficient to generate atonic periods by itself. The chronic medullary animal never shows periods of atonia (Siegel et al., 1986b) . In the otherwise intact animal, small lesions in the dorsolateral pons permanently block the atonia of REM sleep (Jouvet and Delorme, 1965; Henley and Morrison, 1974) . Thus, activity in the pons is required for spontaneous atonia. We hypothesize that the pontine triggering of atonia is mediated by medullary mechanisms consisting of glutamate-and ACh-sensitive neurons localized in NMC and NPM, respectively. This hypothesis is supported by our finding that glutamate antagonists injected into the rostra1 medulla and atropine injected in the caudal medulla block atonia elicited from pontine carbachol injection. Since pontine injections of both ACh and glutamate trigger atonia, the pontine neurons triggering atonia are either responsive to both substances or consist of 2 distinct, but anatomically intermingled, groups of neurons, one group being responsive to glutamate and the other to ACh. The dorsolateral pontine region is known to project to the NMC (Sakai, 1980) . We hypothesize that this projection activates non-NMDA glutamate receptors. Our results suggest that the NPM is also a link in the atonia pathway. Since there are few cholinergic neurons in the NMC of the cat (Kimura et al., 198 1; Jones and Yang, 1985; Reiner and Vincent, 1986; Jones and Beaudet, 1987) , we hypothesize that the cholinoceptive NPM receives projections from the dorsolateral pontine choline& cell groups adjacent to the pontine cholinoceptive region or from lateral medullary cholinergic neurons (Jones and Beaudet, 1987) . Both NMC and NPM have massive spinal projections (Torvik and Brodal, 1957; Tohyama et al., 1979; Hayes and Rustioni, 198 1; Zemlan et al., 1984; Jones et al., 1986) and have been shown to produce IPSPs in cervical (Peterson et al., 1979) and lumbar (Jankowska et al., 1968) Figure 6 . Effect of microinjection of ACh into the n. paramedianus of the medial medulla in the intact, unanesthetized cat. During baseline periods EMG is present in quiet waking (sample shows lowest waking EMG level seen in 6 hr baseline recording), is diminished in non-REM sleep, and is absent in REM sleep (ECG visible). Unilateral ACh microinjection reduces tone below the lowest waking and non-REM sleep levels, although not quite to the levels seen in REM sleen. EMG returns to baseline levels within 5-10 min. Effects were reproducible with repeated injections spaced 4 d apart.
and excitatory amino acids microinjected in the vicinity of the NMC, especially in the raphe magnus, have been shown to affect spinal inhibition related to nociception, but these effects have been reported to occur without alterations in muscle tone (Aimone and Gebhart, 1986; Brodie and Proudfit, 1986) . The pontine and rostra1 medullary regions, which can be chemically activated to produce atonia, contain subpopulations of neurons that are selectively active during the atonia of REM sleep and during waking postures associated with reduced muscle tone (Netick et al., 1977; Siegel et al., 1979; Kanamori et al., 1980; Chase et al., 198 1) . Narcoleptics periodically experience episodes of cataplexy, a sudden loss of muscle tone arising in waking without loss of consciousness. Recent work has shown that cells localized to the NMC are selectively active during these cataplectic attacks . Narcoleptic animals have elevated levels of cholinergic receptors in the nucleus pontis centralis oralis (Boehme et al., 1984) . Thus, activation ofthis pontomedullary circuit is likely to mediate the sudden loss of muscle tone in cataplexy, as well as the normal atonia of REM sleep.
The caudal medullary region, centered on NPM, has not been previously implicated in the control of atonia, although shortlatency IPSPs in neck motoneurons resulting from electrical stimulation of the NPM have been reported (Peterson et al., 1978) . Neurons in the NPM have been shown to be activated by iontophoresis of ACh (Avanzino et al., 1966 (Avanzino et al., , 1975 . This region receives input from baroreceptors and has been hypothesized to serve as a center for the integration of postural and blood pressure information (Homma et al., 1970; Miura and Reis, 197 1; Doba and Reis, 1972; Elisevich et al., 1985 Elisevich et al., , 1987 . Cataplectic attacks are preceded by marked increases in heart rate and can be precipitated by blood pressure increases (Siegel et al., 1986a (Siegel et al., , 1989 . The paramedian region may be responsible for these effects. Future studies should be directed at characterizing the interactions between NMC, NPM, and peri-locus coeruleus (Y in generating atonia during REM sleep and cataplexy and in their role in other diseases characterized by motor tone abnormalities.
